Last Updated on January 13, 2024 by The Health Master
Biopharmaceutical firm Biocon Biologics said that it was issued 8 observations by the US Food and Drug Administration (USFDA) at its Insulins Manufacturing Facility in Malaysia.
The USFDA issued a Form 483 — a form listing violations — after inspections between July 10 and July 20 this year.
The USFDA issues a Form 483 if its investigators spot any conditions that in their judgement may constitute violations of the US Food Drug and Cosmetic (FD&C) Act and related laws.
The US drug regulator issued 6 observations for Drug Substance, Drug Product units and Quality Control laboratories and 2 observations for the Delivery Devices unit of Biocon Sdn Bhd, Malaysia, a subsidiary of Biocon Biologics.
These observations mostly concern improving operating practices and strengthening training initiatives.
No systemic non-compliance or breaches of data integrity were found during the inspections, Biocon said in its statement with the stock exchanges.
Biocon is confident of addressing these observations expeditiously, and remains committed to global standards of quality and compliance, its statement said.
“We will submit a Corrective and Preventive Action (CAPA) plan to the USFDA in a timely manner and are confident of addressing these observations expeditiously.
Biocon Biologics remains committed to global standards of Quality and Compliance,” Biocon spokesperson’s statement read.
At the close of market hours on July 21, Biocon was quoting at Rs 264, down Rs 2.50 or 0.94 percent on the BSE.
NSQ Drug: Route cause analysis and CAPA
USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad
USFDA issues Form 483 to Lupin with 2 observations: Nagpur
USFDA completes inspection of Granules India in two facilities
USFDA completes inspection at Ajanta Pharma with zero observations: Gujarat
USFDA concludes inspection at Zydus with zero observation
USFDA completes inspection of Dr Reddy’s with zero observation
Indian, Chinese Pharma Companies getting most FDA warnings
USFDA gives nod for Blood Cancer treatment
FDCs Ban case: Delhi High Court grants time for Centre and Pharma Companies to Submit Affidavits
Indian Pharma Industry wants to end multiple inspections by USFDA
Govt asks Medical Stores not to sell painkillers without prescription: Delhi
DCGI plans unified Online Portal for Drug Quality and Patient Safety
Committee asks USFDA to submit details on inspection of Pharma Companies in India and China
AHUs, Air Types, Air Changes and their Functions in Pharma Industry
Third Phase of Risk Based Inspections on Pharma Companies concluded: Gujarat
Pharmacy Council appoints four Pharmacy Inspectors: Karnataka
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
